Innovation Accelerator

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has introduced the Innovation Accelerator service to streamline the development and regulation of novel healthcare products. This service is designed to provide developers of medicines, medical devices, and blood components with direct access to scientific expertise and regulatory guidance. By consolidating the Innovation Office, the Regulatory Advice Service for Regenerative Medicines (RASRM), and Regulatory Science teams, the agency offers a centralized hub for advice and horizon scanning. Operating under the broader regulatory framework of the Innovative Licensing and Access Pathway (ILAP), the initiative focuses on proactive engagement rather than enforcement. While this guidance does not stem from specific violations or inspections, it outlines the infrastructure available to help innovators navigate safety standards and licensing requirements. Developers are encouraged to utilize these advisory services to ensure that innovative products, including software-based medical devices, comply with scientific benchmarks and reach the market more efficiently through enhanced signposting and strategic regulatory support.